Skip to main content

Kerins Patrick J's Form 4 filing

Enliven Therapeutics, Inc. (ELVN) · filed Jan 20, 2022

Accession no.
0001209191-22-004110
Filed
Jan 20, 2022, 5:20 PM ET
Trade date
Jan 18-20, 2022
Filing delay
2 days
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 3 non-derivative transactions. Open-market sales total $48.7K. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Kerins Patrick JCIK 000123511210% Owner
Sandell Scott DCIK 000123728910% Owner
Baskett ForestCIK 000127763110% Owner
New Enterprise Associates 14, L.P.CIK 000154432810% Owner
NEA Partners 14, L.P.CIK 000155153110% Owner
Nea 14 GP, LtdCIK 000155153210% Owner
Sonsini Peter W.CIK 000155980710% Owner
Florence Anthony A. Jr.CIK 000155982710% Owner

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Jan 18, 2022Common StockSSaleDisposed−6,848$1.89−$12,926.973,459,866Direct
Jan 19, 2022Common StockSSaleDisposed−13,412$1.82−$24,413.863,446,454Direct
Jan 20, 2022Common StockSSaleDisposed−6,295$1.81−$11,385.143,440,159Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

No transaction price on this filing refers to a footnote.

Read the full filing on SEC EDGAR (opens in a new tab)